The long-term efficacy and safety of canagliflozin , a sodium glucose co-transporter 2 inhibitor , was evaluated over 104weeks in patients aged 55-80years with type 2 diabetes mellitus ( T2DM ) inadequately controlled on a stable antihyperglycaemic agent regimen .